Nephros, Inc. (NEPH) 10-Year Financial Performance & Capital Metrics

NEPH • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesAdvanced Wound Care

AboutNephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.Show more

Revenue $14M -0.5%
EBITDA $143K +110.4%
Net Income $74K +104.7%
EPS (Diluted) 0.01 +104.7%
Gross Margin 61.59% +4.3%
EBITDA Margin 1.01% +110.4%
Operating Margin 0.04% +100.4%
Net Margin 0.52% +104.7%
ROE 0.87% +104.8%
ROIC 0.07% +100.4%
Debt/Equity 0.16 -25.2%
Interest Coverage 6.00 +100.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)
✓Efficient asset utilization: 1.3x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.27%

5Y6.51%

3Y11.5%

TTM32.36%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM259.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM255.83%

ROCE

10Y Avg-53.93%

5Y Avg-20.75%

3Y Avg-17.1%

Latest0.06%

Peer Comparison

Advanced Wound Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
NEPHNephros, Inc.	46.54M	4.38	625.71	-0.53%	8.26%	14.8%	0.16
NXGLNEXGEL, Inc.	14.17M	1.74	-3.48	112.47%	-24.69%	-51.65%	0.46
SMTISanara MedTech Inc.	212.4M	23.77	-20.85	33.36%	-36.79%	-6.11%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.94M	2.32M	3.81M	5.69M	10.33M	8.56M	10.22M	9.97M	14.24M	14.16M
Revenue Growth %	0.11%	0.19%	0.64%	0.49%	0.82%	-0.17%	0.19%	-0.02%	0.43%	-0.01%
Cost of Goods Sold+	884K	1.03M	1.52M	2.48M	4.25M	3.65M	4.58M	5.24M	5.83M	5.44M
COGS % of Revenue	0.45%	0.44%	0.4%	0.44%	0.41%	0.43%	0.45%	0.53%	0.41%	0.38%
Gross Profit+	1.06M	1.29M	2.29M	3.2M	6.08M	4.91M	5.63M	4.73M	8.4M	8.72M
Gross Margin %	0.55%	0.56%	0.6%	0.56%	0.59%	0.57%	0.55%	0.47%	0.59%	0.62%
Gross Profit Growth %	-0.12%	0.22%	0.77%	0.4%	0.9%	-0.19%	0.15%	-0.16%	0.78%	0.04%
Operating Expenses+	4.48M	4.16M	4.52M	6.22M	9.24M	9.19M	8.88M	9.07M	10M	8.72M
OpEx % of Revenue	2.31%	1.79%	1.19%	1.09%	0.89%	1.07%	0.87%	0.91%	0.7%	0.62%
Selling, General & Admin	3.44M	2.85M	3.3M	4.52M	6.12M	6.47M	7.2M	7.59M	8.91M	7.68M
SG&A % of Revenue	1.77%	1.23%	0.87%	0.79%	0.59%	0.76%	0.7%	0.76%	0.63%	0.54%
Research & Development	826K	1.08M	1M	1.54M	3.09M	2.76M	1.5M	1.25M	873K	906K
R&D % of Revenue	0.42%	0.47%	0.26%	0.27%	0.3%	0.32%	0.15%	0.13%	0.06%	0.06%
Other Operating Expenses	212K	230K	218K	-35K	30K	-37K	192K	218K	214K	135K
Operating Income+	-3.42M	-2.87M	-2.23M	-3.02M	-3.15M	-4.28M	-3.25M	-4.33M	-1.59M	6K
Operating Margin %	-1.76%	-1.24%	-0.58%	-0.53%	-0.31%	-0.5%	-0.32%	-0.43%	-0.11%	0%
Operating Income Growth %	-0.28%	0.16%	0.22%	-0.35%	-0.05%	-0.35%	0.24%	-0.33%	0.63%	1%
EBITDA+	-3.21M	-2.64M	-2.01M	-2.85M	-2.96M	-4.07M	-3M	-3.76M	-1.38M	143K
EBITDA Margin %	-1.65%	-1.14%	-0.53%	-0.5%	-0.29%	-0.48%	-0.29%	-0.38%	-0.1%	0.01%
EBITDA Growth %	-0.31%	0.18%	0.24%	-0.42%	-0.04%	-0.38%	0.26%	-0.25%	0.63%	1.1%
D&A (Non-Cash Add-back)	212K	230K	218K	163K	200K	208K	252K	571K	214K	137K
EBIT	-3.05M	-2.86M	-2.3M	-3.25M	-3.21M	-4.42M	-2.74M	-4.26M	-1.57M	90K
Net Interest Income+	-42K	-167K	-298K	-168K	-195K	-99K	-31K	-6K	62K	93K
Interest Income	0	5K	4K	4K	0	11K	10K	14K	64K	94K
Interest Expense	42K	172K	302K	172K	195K	110K	41K	20K	2K	1K
Other Income/Expense	333K	-163K	-372K	-402K	-249K	-251K	468K	58K	18K	83K
Pretax Income+	-3.09M	-3.03M	-2.6M	-3.42M	-3.4M	-4.53M	-2.78M	-4.28M	-1.57M	89K
Pretax Margin %	-1.59%	-1.31%	-0.68%	-0.6%	-0.33%	-0.53%	-0.27%	-0.43%	-0.11%	0.01%
Income Tax+	0	0	-1.79M	-93K	-225K	0	0	0	0	15K
Effective Tax Rate %	1%	1%	0.31%	1%	1%	1.05%	1.48%	1.73%	1%	0.83%
Net Income+	-3.09M	-3.03M	-809K	-3.4M	-3.42M	-4.77M	-4.11M	-7.38M	-1.57M	74K
Net Margin %	-1.59%	-1.31%	-0.21%	-0.6%	-0.33%	-0.56%	-0.4%	-0.74%	-0.11%	0.01%
Net Income Growth %	0.58%	0.02%	0.73%	-3.21%	-0.01%	-0.39%	0.14%	-0.8%	0.79%	1.05%
Net Income (Continuing)	-3.09M	-3.03M	-809K	-3.33M	-3.18M	-4.53M	-2.78M	-4.28M	-1.57M	74K
Discontinued Operations	0	0	0	0	0	0	-1.08M	-2.83M	0	0
Minority Interest	0	0	0	3M	3.01M	3.05M	3.05M	3.29M	0	0
EPS (Diluted)+	-0.80	-0.56	-0.14	-0.50	-0.42	-0.52	-0.41	-0.72	-0.15	0.01
EPS Growth %	0.71%	0.3%	0.75%	-2.57%	0.16%	-0.24%	0.21%	-0.76%	0.79%	1.05%
EPS (Basic)	-0.80	-0.56	-0.14	-0.50	-0.42	-0.52	-0.41	-0.72	-0.15	0.01
Diluted Shares Outstanding	3.86M	5.4M	5.88M	6.85M	7.54M	9.08M	10.02M	10.3M	10.39M	10.6M
Basic Shares Outstanding	3.86M	5.4M	5.88M	6.85M	7.54M	9.08M	10.02M	10.3M	10.39M	10.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.46M	1.26M	3.81M	8.17M	8.3M	15.15M	13.63M	8.26M	8.4M	8.3M
Cash & Short-Term Investments	1.25M	302K	2.21M	4.58M	4.17M	8.25M	6.97M	3.63M	4.31M	3.76M
Cash Only	1.25M	275K	2.19M	4.58M	4.17M	8.25M	6.97M	3.63M	4.31M	3.76M
Short-Term Investments	0	27K	20K	0	0	0	0	0	0	0
Accounts Receivable	397K	388K	836K	1.45M	1.27M	1.36M	1.64M	1.29M	1.5M	1.78M
Days Sales Outstanding	74.54	61.04	80.11	93.19	44.86	58.15	58.62	47.06	38.35	45.9
Inventory	591K	479K	674K	1.86M	2.56M	5.3M	4.46M	3.15M	2.47M	2.62M
Days Inventory Outstanding	244.02	170.4	162.17	273.9	220.03	530.69	355.29	219.46	154.56	175.49
Other Current Assets	166K	29K	26K	231K	0	0	351K	0	132K	142K
Total Non-Current Assets+	1.51M	1.41M	1.17M	2.38M	3.33M	3.36M	4.02M	2.74M	3.46M	2.91M
Property, Plant & Equipment	12K	70K	52K	91K	1.19M	1.33M	686K	1.1M	1.96M	1.54M
Fixed Asset Turnover	162.00x	33.14x	73.25x	62.49x	8.71x	6.43x	14.89x	9.07x	7.27x	9.21x
Goodwill	0	0	0	748K	759K	759K	759K	759K	759K	759K
Intangible Assets	1.49M	1.26M	1.07M	1.53M	1.35M	1.18M	1M	825K	652K	565K
Long-Term Investments	21K	61K	39K	0	0	36K	0	0	0	0
Other Non-Current Assets	21K	21K	11K	18K	32K	53K	1.57M	54K	86K	50K
Total Assets+	3.97M	2.68M	4.98M	10.56M	11.63M	18.51M	17.65M	11M	11.86M	11.21M
Asset Turnover	0.49x	0.87x	0.76x	0.54x	0.89x	0.46x	0.58x	0.91x	1.20x	1.26x
Asset Growth %	0.18%	-0.33%	0.86%	1.12%	0.1%	0.59%	-0.05%	-0.38%	0.08%	-0.05%
Total Current Liabilities+	959K	895K	1.87M	2.65M	2.43M	1.32M	2.39M	1.41M	2.11M	1.56M
Accounts Payable	652K	585K	872K	836K	959K	423K	1.33M	740K	873K	649K
Days Payables Outstanding	269.21	208.11	209.81	122.84	82.36	42.32	106.22	51.51	54.63	43.55
Short-Term Debt	0	0	711K	1.19M	771K	229K	248K	71K	0	0
Deferred Revenue (Current)	70K	70K	70K	396K	0	0	0	0	0	0
Other Current Liabilities	52K	0	0	590K	300K	0	51K	0	0	0
Current Ratio	2.57x	1.41x	2.04x	3.08x	3.42x	11.44x	5.70x	5.85x	3.98x	5.31x
Quick Ratio	1.95x	0.88x	1.68x	2.38x	2.36x	7.43x	3.84x	3.62x	2.81x	3.64x
Cash Conversion Cycle	49.35	23.33	32.47	244.25	182.53	546.52	307.69	215.01	138.28	177.84
Total Non-Current Liabilities+	347K	1.12M	1.16M	1.11M	1.51M	1.61M	511K	706K	1.39M	1.06M
Long-Term Debt	0	838K	954K	843K	623K	853K	99K	1K	0	0
Capital Lease Obligations	0	0	0	0	889K	759K	340K	705K	1.39M	1.06M
Deferred Tax Liabilities	0	-278K	-208K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	263K	0	0	72K	0	0	0
Total Liabilities	1.31M	2.01M	3.03M	3.76M	3.94M	2.94M	2.9M	2.12M	3.5M	2.63M
Total Debt+	0	838K	1.67M	2.03M	2.54M	2.17M	1M	1.09M	1.84M	1.41M
Net Debt	-1.25M	563K	-529K	-2.55M	-1.62M	-6.08M	-5.97M	-2.54M	-2.47M	-2.35M
Debt / Equity	-	1.26x	0.85x	0.30x	0.33x	0.14x	0.07x	0.12x	0.22x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	9.87x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-16.43x
Interest Coverage	-81.45x	-16.68x	-7.37x	-17.53x	-16.18x	-38.86x	-79.32x	-216.75x	-796.50x	6.00x
Total Equity+	2.66M	667K	1.95M	6.8M	7.69M	15.57M	14.75M	8.88M	8.36M	8.59M
Equity Growth %	1.47%	-0.75%	1.92%	2.49%	0.13%	1.03%	-0.05%	-0.4%	-0.06%	0.03%
Book Value per Share	0.69	0.12	0.33	0.99	1.02	1.72	1.47	0.86	0.80	0.81
Total Shareholders' Equity	2.66M	667K	1.95M	3.8M	4.67M	12.52M	11.7M	5.59M	8.36M	8.59M
Common Stock	49K	50K	55K	64K	8K	10K	10K	10K	10K	11K
Retained Earnings	-117.25M	-120.28M	-121.11M	-124.15M	-127.33M	-131.86M	-135.72M	-142.83M	-144.41M	-144.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	71K	67K	77K	71K	65K	74K	64K	0	0	0
Minority Interest	0	0	0	3M	3.01M	3.05M	3.05M	3.29M	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.81M	-2.11M	-77K	-3.66M	-2.28M	-6.9M	-1.42M	-3.23M	827K	-492K
Operating CF Margin %	-1.96%	-0.91%	-0.02%	-0.64%	-0.22%	-0.81%	-0.14%	-0.32%	0.06%	-0.03%
Operating CF Growth %	-0.53%	0.45%	0.96%	-46.56%	0.38%	-2.03%	0.79%	-1.28%	1.26%	-1.59%
Net Income	-3.09M	-3.03M	-809K	-3.33M	-3.18M	-4.53M	-3.87M	-4.55M	-1.57M	74K
Depreciation & Amortization	212K	230K	218K	163K	200K	208K	252K	351K	214K	137K
Stock-Based Compensation	489K	597K	772K	985K	1.33M	779K	1.26M	952K	1.05M	153K
Deferred Taxes	8K	-566K	0	322K	56K	0	0	0	0	0
Other Non-Cash Items	-270K	677K	135K	45K	-105K	129K	56K	-213K	648K	698K
Working Capital Changes	-1.17M	-18K	-393K	-1.85M	-580K	-3.49M	883K	229K	488K	-1.55M
Change in Receivables	-302K	-17K	-416K	-484K	392K	-333K	-278K	357K	-221K	-285K
Change in Inventory	-405K	103K	-195K	-1.08M	-735K	-2.76M	296K	915K	387K	-407K
Change in Payables	-176K	-76K	268K	-130K	119K	-538K	908K	-593K	133K	-220K
Cash from Investing+	-13K	-45K	0	-991K	-151K	-239K	-85K	-137K	-75K	-50K
Capital Expenditures	-13K	-45K	0	0	-14K	-239K	-36K	-137K	-75K	-55K
CapEx % of Revenue	0.01%	0.02%	-	-	0%	0.03%	0%	0.01%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-49K	0	0	5K
Cash from Financing+	3.79M	1.19M	1.99M	7.05M	2.02M	11.22M	237K	34K	-79K	-5K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-73K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.52M	1K	100K	3.14M	658K	85K	0	157K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.83M	-2.16M	-77K	-3.66M	-2.29M	-7.14M	-1.45M	-3.37M	752K	-547K
FCF Margin %	-1.97%	-0.93%	-0.02%	-0.64%	-0.22%	-0.83%	-0.14%	-0.34%	0.05%	-0.04%
FCF Growth %	-0.53%	0.44%	0.96%	-46.56%	0.37%	-2.12%	0.8%	-1.32%	1.22%	-1.73%
FCF per Share	-0.99	-0.40	-0.01	-0.53	-0.30	-0.79	-0.15	-0.33	0.07	-0.05
FCF Conversion (FCF/Net Income)	1.24x	0.70x	0.10x	1.08x	0.67x	1.45x	0.35x	0.44x	-0.53x	-6.65x
Interest Paid	43K	113K	148K	150K	139K	93K	41K	0	0	0
Taxes Paid	5K	11K	7K	4K	5K	22K	79K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-115.92%	-182.05%	-61.83%	-77.78%	-47.21%	-40.98%	-27.09%	-62.48%	-18.27%	0.87%
Return on Invested Capital (ROIC)	-	-162.64%	-125.95%	-79.83%	-45.88%	-41.2%	-26.7%	-43.02%	-19.54%	0.07%
Gross Margin	54.53%	55.78%	60.17%	56.32%	58.87%	57.39%	55.13%	47.43%	59.03%	61.59%
Net Margin	-158.85%	-130.69%	-21.24%	-59.82%	-33.09%	-55.67%	-40.2%	-74%	-11.06%	0.52%
Debt / Equity	-	1.26x	0.85x	0.30x	0.33x	0.14x	0.07x	0.12x	0.22x	0.16x
Interest Coverage	-81.45x	-16.68x	-7.37x	-17.53x	-16.18x	-38.86x	-79.32x	-216.75x	-796.50x	6.00x
FCF Conversion	1.24x	0.70x	0.10x	1.08x	0.67x	1.45x	0.35x	0.44x	-0.53x	-6.65x
Revenue Growth	11.21%	19.34%	64.18%	49.3%	81.71%	-17.16%	19.34%	-2.37%	42.74%	-0.53%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Royalty and Other Revenues	-	152K	-	-	46K	-	127K
Royalty and Other Revenues Growth	-	-	-	-	-	-	-
Other Revenue	29K	77K	40K	121K	46K	97K	121K
Other Revenue Growth	-	165.52%	-48.05%	202.50%	-61.98%	110.87%	24.74%
Royalty And Other Revenues	-	-	-	-	-	128K	-
Royalty And Other Revenues Growth	-	-	-	-	-	-	-
License Royalty and Other Revenue	-	-	108K	200K	-	-	-
License Royalty and Other Revenue Growth	-	-	-	85.19%	-	-	-

Frequently Asked Questions

Growth & Financials

Nephros, Inc. (NEPH) reported $17.9M in revenue for fiscal year 2024. This represents a 710% increase from $2.2M in 2011.

Nephros, Inc. (NEPH) saw revenue decline by 0.5% over the past year.

Yes, Nephros, Inc. (NEPH) is profitable, generating $1.5M in net income for fiscal year 2024 (0.5% net margin).

Dividend & Returns

Nephros, Inc. (NEPH) has a return on equity (ROE) of 0.9%. This is below average, suggesting room for improvement.

Nephros, Inc. (NEPH) generated $2.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...

Nephros, Inc. (NEPH) 10-Year Financial Performance & Capital Metrics

NEPH • • Industrial / General

HealthcareMedical InstrumentsWound Care & Therapeutic DevicesAdvanced Wound Care

Revenue $14M -0.5%
EBITDA $143K +110.4%
Net Income $74K +104.7%
EPS (Diluted) 0.01 +104.7%
Gross Margin 61.59% +4.3%
EBITDA Margin 1.01% +110.4%
Operating Margin 0.04% +100.4%
Net Margin 0.52% +104.7%
ROE 0.87% +104.8%
ROIC 0.07% +100.4%
Debt/Equity 0.16 -25.2%
Interest Coverage 6.00 +100.8%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Momentum leader: RS Rating 83 (top 17%)
✓Efficient asset utilization: 1.3x turnover

✗Weaknesses

✗Negative free cash flow
✗Trading more than 30% below 52-week high

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y23.27%

5Y6.51%

3Y11.5%

TTM32.36%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM259.42%

EPS CAGR

10Y-

5Y-

3Y-

TTM255.83%

ROCE

10Y Avg-53.93%

5Y Avg-20.75%

3Y Avg-17.1%

Latest0.06%

Peer Comparison

Advanced Wound Care

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	Debt/Equity
NEPHNephros, Inc.	46.54M	4.38	625.71	-0.53%	8.26%	14.8%	0.16
NXGLNEXGEL, Inc.	14.17M	1.74	-3.48	112.47%	-24.69%	-51.65%	0.46
SMTISanara MedTech Inc.	212.4M	23.77	-20.85	33.36%	-36.79%	-6.11%	0.83

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	1.94M	2.32M	3.81M	5.69M	10.33M	8.56M	10.22M	9.97M	14.24M	14.16M
Revenue Growth %	0.11%	0.19%	0.64%	0.49%	0.82%	-0.17%	0.19%	-0.02%	0.43%	-0.01%
Cost of Goods Sold+	884K	1.03M	1.52M	2.48M	4.25M	3.65M	4.58M	5.24M	5.83M	5.44M
COGS % of Revenue	0.45%	0.44%	0.4%	0.44%	0.41%	0.43%	0.45%	0.53%	0.41%	0.38%
Gross Profit+	1.06M	1.29M	2.29M	3.2M	6.08M	4.91M	5.63M	4.73M	8.4M	8.72M
Gross Margin %	0.55%	0.56%	0.6%	0.56%	0.59%	0.57%	0.55%	0.47%	0.59%	0.62%
Gross Profit Growth %	-0.12%	0.22%	0.77%	0.4%	0.9%	-0.19%	0.15%	-0.16%	0.78%	0.04%
Operating Expenses+	4.48M	4.16M	4.52M	6.22M	9.24M	9.19M	8.88M	9.07M	10M	8.72M
OpEx % of Revenue	2.31%	1.79%	1.19%	1.09%	0.89%	1.07%	0.87%	0.91%	0.7%	0.62%
Selling, General & Admin	3.44M	2.85M	3.3M	4.52M	6.12M	6.47M	7.2M	7.59M	8.91M	7.68M
SG&A % of Revenue	1.77%	1.23%	0.87%	0.79%	0.59%	0.76%	0.7%	0.76%	0.63%	0.54%
Research & Development	826K	1.08M	1M	1.54M	3.09M	2.76M	1.5M	1.25M	873K	906K
R&D % of Revenue	0.42%	0.47%	0.26%	0.27%	0.3%	0.32%	0.15%	0.13%	0.06%	0.06%
Other Operating Expenses	212K	230K	218K	-35K	30K	-37K	192K	218K	214K	135K
Operating Income+	-3.42M	-2.87M	-2.23M	-3.02M	-3.15M	-4.28M	-3.25M	-4.33M	-1.59M	6K
Operating Margin %	-1.76%	-1.24%	-0.58%	-0.53%	-0.31%	-0.5%	-0.32%	-0.43%	-0.11%	0%
Operating Income Growth %	-0.28%	0.16%	0.22%	-0.35%	-0.05%	-0.35%	0.24%	-0.33%	0.63%	1%
EBITDA+	-3.21M	-2.64M	-2.01M	-2.85M	-2.96M	-4.07M	-3M	-3.76M	-1.38M	143K
EBITDA Margin %	-1.65%	-1.14%	-0.53%	-0.5%	-0.29%	-0.48%	-0.29%	-0.38%	-0.1%	0.01%
EBITDA Growth %	-0.31%	0.18%	0.24%	-0.42%	-0.04%	-0.38%	0.26%	-0.25%	0.63%	1.1%
D&A (Non-Cash Add-back)	212K	230K	218K	163K	200K	208K	252K	571K	214K	137K
EBIT	-3.05M	-2.86M	-2.3M	-3.25M	-3.21M	-4.42M	-2.74M	-4.26M	-1.57M	90K
Net Interest Income+	-42K	-167K	-298K	-168K	-195K	-99K	-31K	-6K	62K	93K
Interest Income	0	5K	4K	4K	0	11K	10K	14K	64K	94K
Interest Expense	42K	172K	302K	172K	195K	110K	41K	20K	2K	1K
Other Income/Expense	333K	-163K	-372K	-402K	-249K	-251K	468K	58K	18K	83K
Pretax Income+	-3.09M	-3.03M	-2.6M	-3.42M	-3.4M	-4.53M	-2.78M	-4.28M	-1.57M	89K
Pretax Margin %	-1.59%	-1.31%	-0.68%	-0.6%	-0.33%	-0.53%	-0.27%	-0.43%	-0.11%	0.01%
Income Tax+	0	0	-1.79M	-93K	-225K	0	0	0	0	15K
Effective Tax Rate %	1%	1%	0.31%	1%	1%	1.05%	1.48%	1.73%	1%	0.83%
Net Income+	-3.09M	-3.03M	-809K	-3.4M	-3.42M	-4.77M	-4.11M	-7.38M	-1.57M	74K
Net Margin %	-1.59%	-1.31%	-0.21%	-0.6%	-0.33%	-0.56%	-0.4%	-0.74%	-0.11%	0.01%
Net Income Growth %	0.58%	0.02%	0.73%	-3.21%	-0.01%	-0.39%	0.14%	-0.8%	0.79%	1.05%
Net Income (Continuing)	-3.09M	-3.03M	-809K	-3.33M	-3.18M	-4.53M	-2.78M	-4.28M	-1.57M	74K
Discontinued Operations	0	0	0	0	0	0	-1.08M	-2.83M	0	0
Minority Interest	0	0	0	3M	3.01M	3.05M	3.05M	3.29M	0	0
EPS (Diluted)+	-0.80	-0.56	-0.14	-0.50	-0.42	-0.52	-0.41	-0.72	-0.15	0.01
EPS Growth %	0.71%	0.3%	0.75%	-2.57%	0.16%	-0.24%	0.21%	-0.76%	0.79%	1.05%
EPS (Basic)	-0.80	-0.56	-0.14	-0.50	-0.42	-0.52	-0.41	-0.72	-0.15	0.01
Diluted Shares Outstanding	3.86M	5.4M	5.88M	6.85M	7.54M	9.08M	10.02M	10.3M	10.39M	10.6M
Basic Shares Outstanding	3.86M	5.4M	5.88M	6.85M	7.54M	9.08M	10.02M	10.3M	10.39M	10.53M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	2.46M	1.26M	3.81M	8.17M	8.3M	15.15M	13.63M	8.26M	8.4M	8.3M
Cash & Short-Term Investments	1.25M	302K	2.21M	4.58M	4.17M	8.25M	6.97M	3.63M	4.31M	3.76M
Cash Only	1.25M	275K	2.19M	4.58M	4.17M	8.25M	6.97M	3.63M	4.31M	3.76M
Short-Term Investments	0	27K	20K	0	0	0	0	0	0	0
Accounts Receivable	397K	388K	836K	1.45M	1.27M	1.36M	1.64M	1.29M	1.5M	1.78M
Days Sales Outstanding	74.54	61.04	80.11	93.19	44.86	58.15	58.62	47.06	38.35	45.9
Inventory	591K	479K	674K	1.86M	2.56M	5.3M	4.46M	3.15M	2.47M	2.62M
Days Inventory Outstanding	244.02	170.4	162.17	273.9	220.03	530.69	355.29	219.46	154.56	175.49
Other Current Assets	166K	29K	26K	231K	0	0	351K	0	132K	142K
Total Non-Current Assets+	1.51M	1.41M	1.17M	2.38M	3.33M	3.36M	4.02M	2.74M	3.46M	2.91M
Property, Plant & Equipment	12K	70K	52K	91K	1.19M	1.33M	686K	1.1M	1.96M	1.54M
Fixed Asset Turnover	162.00x	33.14x	73.25x	62.49x	8.71x	6.43x	14.89x	9.07x	7.27x	9.21x
Goodwill	0	0	0	748K	759K	759K	759K	759K	759K	759K
Intangible Assets	1.49M	1.26M	1.07M	1.53M	1.35M	1.18M	1M	825K	652K	565K
Long-Term Investments	21K	61K	39K	0	0	36K	0	0	0	0
Other Non-Current Assets	21K	21K	11K	18K	32K	53K	1.57M	54K	86K	50K
Total Assets+	3.97M	2.68M	4.98M	10.56M	11.63M	18.51M	17.65M	11M	11.86M	11.21M
Asset Turnover	0.49x	0.87x	0.76x	0.54x	0.89x	0.46x	0.58x	0.91x	1.20x	1.26x
Asset Growth %	0.18%	-0.33%	0.86%	1.12%	0.1%	0.59%	-0.05%	-0.38%	0.08%	-0.05%
Total Current Liabilities+	959K	895K	1.87M	2.65M	2.43M	1.32M	2.39M	1.41M	2.11M	1.56M
Accounts Payable	652K	585K	872K	836K	959K	423K	1.33M	740K	873K	649K
Days Payables Outstanding	269.21	208.11	209.81	122.84	82.36	42.32	106.22	51.51	54.63	43.55
Short-Term Debt	0	0	711K	1.19M	771K	229K	248K	71K	0	0
Deferred Revenue (Current)	70K	70K	70K	396K	0	0	0	0	0	0
Other Current Liabilities	52K	0	0	590K	300K	0	51K	0	0	0
Current Ratio	2.57x	1.41x	2.04x	3.08x	3.42x	11.44x	5.70x	5.85x	3.98x	5.31x
Quick Ratio	1.95x	0.88x	1.68x	2.38x	2.36x	7.43x	3.84x	3.62x	2.81x	3.64x
Cash Conversion Cycle	49.35	23.33	32.47	244.25	182.53	546.52	307.69	215.01	138.28	177.84
Total Non-Current Liabilities+	347K	1.12M	1.16M	1.11M	1.51M	1.61M	511K	706K	1.39M	1.06M
Long-Term Debt	0	838K	954K	843K	623K	853K	99K	1K	0	0
Capital Lease Obligations	0	0	0	0	889K	759K	340K	705K	1.39M	1.06M
Deferred Tax Liabilities	0	-278K	-208K	0	0	0	0	0	0	0
Other Non-Current Liabilities	0	0	0	263K	0	0	72K	0	0	0
Total Liabilities	1.31M	2.01M	3.03M	3.76M	3.94M	2.94M	2.9M	2.12M	3.5M	2.63M
Total Debt+	0	838K	1.67M	2.03M	2.54M	2.17M	1M	1.09M	1.84M	1.41M
Net Debt	-1.25M	563K	-529K	-2.55M	-1.62M	-6.08M	-5.97M	-2.54M	-2.47M	-2.35M
Debt / Equity	-	1.26x	0.85x	0.30x	0.33x	0.14x	0.07x	0.12x	0.22x	0.16x
Debt / EBITDA	-	-	-	-	-	-	-	-	-	9.87x
Net Debt / EBITDA	-	-	-	-	-	-	-	-	-	-16.43x
Interest Coverage	-81.45x	-16.68x	-7.37x	-17.53x	-16.18x	-38.86x	-79.32x	-216.75x	-796.50x	6.00x
Total Equity+	2.66M	667K	1.95M	6.8M	7.69M	15.57M	14.75M	8.88M	8.36M	8.59M
Equity Growth %	1.47%	-0.75%	1.92%	2.49%	0.13%	1.03%	-0.05%	-0.4%	-0.06%	0.03%
Book Value per Share	0.69	0.12	0.33	0.99	1.02	1.72	1.47	0.86	0.80	0.81
Total Shareholders' Equity	2.66M	667K	1.95M	3.8M	4.67M	12.52M	11.7M	5.59M	8.36M	8.59M
Common Stock	49K	50K	55K	64K	8K	10K	10K	10K	10K	11K
Retained Earnings	-117.25M	-120.28M	-121.11M	-124.15M	-127.33M	-131.86M	-135.72M	-142.83M	-144.41M	-144.33M
Treasury Stock	0	0	0	0	0	0	0	0	0	0
Accumulated OCI	71K	67K	77K	71K	65K	74K	64K	0	0	0
Minority Interest	0	0	0	3M	3.01M	3.05M	3.05M	3.29M	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	-3.81M	-2.11M	-77K	-3.66M	-2.28M	-6.9M	-1.42M	-3.23M	827K	-492K
Operating CF Margin %	-1.96%	-0.91%	-0.02%	-0.64%	-0.22%	-0.81%	-0.14%	-0.32%	0.06%	-0.03%
Operating CF Growth %	-0.53%	0.45%	0.96%	-46.56%	0.38%	-2.03%	0.79%	-1.28%	1.26%	-1.59%
Net Income	-3.09M	-3.03M	-809K	-3.33M	-3.18M	-4.53M	-3.87M	-4.55M	-1.57M	74K
Depreciation & Amortization	212K	230K	218K	163K	200K	208K	252K	351K	214K	137K
Stock-Based Compensation	489K	597K	772K	985K	1.33M	779K	1.26M	952K	1.05M	153K
Deferred Taxes	8K	-566K	0	322K	56K	0	0	0	0	0
Other Non-Cash Items	-270K	677K	135K	45K	-105K	129K	56K	-213K	648K	698K
Working Capital Changes	-1.17M	-18K	-393K	-1.85M	-580K	-3.49M	883K	229K	488K	-1.55M
Change in Receivables	-302K	-17K	-416K	-484K	392K	-333K	-278K	357K	-221K	-285K
Change in Inventory	-405K	103K	-195K	-1.08M	-735K	-2.76M	296K	915K	387K	-407K
Change in Payables	-176K	-76K	268K	-130K	119K	-538K	908K	-593K	133K	-220K
Cash from Investing+	-13K	-45K	0	-991K	-151K	-239K	-85K	-137K	-75K	-50K
Capital Expenditures	-13K	-45K	0	0	-14K	-239K	-36K	-137K	-75K	-55K
CapEx % of Revenue	0.01%	0.02%	-	-	0%	0.03%	0%	0.01%	0.01%	0%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	0	0	0	0	0	0	-49K	0	0	5K
Cash from Financing+	3.79M	1.19M	1.99M	7.05M	2.02M	11.22M	237K	34K	-79K	-5K
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	-73K	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	2.52M	1K	100K	3.14M	658K	85K	0	157K	0	0
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	-3.83M	-2.16M	-77K	-3.66M	-2.29M	-7.14M	-1.45M	-3.37M	752K	-547K
FCF Margin %	-1.97%	-0.93%	-0.02%	-0.64%	-0.22%	-0.83%	-0.14%	-0.34%	0.05%	-0.04%
FCF Growth %	-0.53%	0.44%	0.96%	-46.56%	0.37%	-2.12%	0.8%	-1.32%	1.22%	-1.73%
FCF per Share	-0.99	-0.40	-0.01	-0.53	-0.30	-0.79	-0.15	-0.33	0.07	-0.05
FCF Conversion (FCF/Net Income)	1.24x	0.70x	0.10x	1.08x	0.67x	1.45x	0.35x	0.44x	-0.53x	-6.65x
Interest Paid	43K	113K	148K	150K	139K	93K	41K	0	0	0
Taxes Paid	5K	11K	7K	4K	5K	22K	79K	0	0	0

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	-115.92%	-182.05%	-61.83%	-77.78%	-47.21%	-40.98%	-27.09%	-62.48%	-18.27%	0.87%
Return on Invested Capital (ROIC)	-	-162.64%	-125.95%	-79.83%	-45.88%	-41.2%	-26.7%	-43.02%	-19.54%	0.07%
Gross Margin	54.53%	55.78%	60.17%	56.32%	58.87%	57.39%	55.13%	47.43%	59.03%	61.59%
Net Margin	-158.85%	-130.69%	-21.24%	-59.82%	-33.09%	-55.67%	-40.2%	-74%	-11.06%	0.52%
Debt / Equity	-	1.26x	0.85x	0.30x	0.33x	0.14x	0.07x	0.12x	0.22x	0.16x
Interest Coverage	-81.45x	-16.68x	-7.37x	-17.53x	-16.18x	-38.86x	-79.32x	-216.75x	-796.50x	6.00x
FCF Conversion	1.24x	0.70x	0.10x	1.08x	0.67x	1.45x	0.35x	0.44x	-0.53x	-6.65x
Revenue Growth	11.21%	19.34%	64.18%	49.3%	81.71%	-17.16%	19.34%	-2.37%	42.74%	-0.53%

Revenue by Segment

	2018	2019	2020	2021	2022	2023	2024
Royalty and Other Revenues	-	152K	-	-	46K	-	127K
Royalty and Other Revenues Growth	-	-	-	-	-	-	-
Other Revenue	29K	77K	40K	121K	46K	97K	121K
Other Revenue Growth	-	165.52%	-48.05%	202.50%	-61.98%	110.87%	24.74%
Royalty And Other Revenues	-	-	-	-	-	128K	-
Royalty And Other Revenues Growth	-	-	-	-	-	-	-
License Royalty and Other Revenue	-	-	108K	200K	-	-	-
License Royalty and Other Revenue Growth	-	-	-	85.19%	-	-	-

Frequently Asked Questions

Growth & Financials

Nephros, Inc. (NEPH) reported $17.9M in revenue for fiscal year 2024. This represents a 710% increase from $2.2M in 2011.

Nephros, Inc. (NEPH) saw revenue decline by 0.5% over the past year.

Yes, Nephros, Inc. (NEPH) is profitable, generating $1.5M in net income for fiscal year 2024 (0.5% net margin).

Dividend & Returns

Nephros, Inc. (NEPH) has a return on equity (ROE) of 0.9%. This is below average, suggesting room for improvement.

Nephros, Inc. (NEPH) generated $2.7M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.